Multiply-primed rolling circle amplification (RCA) is a suitable technique for amplification of circular templates and has been used to identify novel human papillomaviruses (HPV). In this study we develop an efficient RCA for whole genome amplification of HPV using HPV-specific primers in clinical samples and establish a protocol for whole genome sequencing using the Sanger method. Amplification of cloned HPV-genomes by RCA was compared using specific primers against random hexamers. Using HPV-specific primers increased the effectiveness on average 15.2 times and the enrichment of HPV relative to human gDNA on average 62.2 times, as compared to using random hexamer. RCA products were sequenced without need for cloning, even when using low-input amounts. The technique was successfully used on 4 patient samples from FTA cards, to generate whole HPV-genome sequences. Degenerated HPV-specific primers for RCA produce DNA of sufficient quality and quantity suitable for sequencing and other potential downstream analyses.
Introduction
Persistent infection with certain types of human papillomavirus (HPV) is the leading risk factor for cervical cancer (Bosch et al., 1995; Munoz et al., 2003; Walboomers et al., 1999) . This group of virus contains over 200 different types, both oncogenic and non-oncogenic, yet new variants continue to be discovered (de Villiers et al., 2004; Lizano et al., 2009) .
Multiply-primed rolling circle amplification (RCA) enables amplification of circular templates, making it suitable for amplification of circular viral genomes in a background of genomic DNA (Dean et al., 2001; Johne and Muller, 2009; Nelson et al., 2002) . This method has led to the discovery of new virus types, including members of the papillomavirus family (Johne et al., 2006; Margeridon et al., 2008; Niel et al., 2005; Rector et al., 2004a Rector et al., , 2005 Tobler et al., 2006; Xu et al., 2008) . The RCA is an isothermal DNA synthesis reaction which uses the phi29 DNA polymerase. This polymerase has a 5 0 -to -3 0 polymerization activity and a 3 0 -to -5 0 ssDNA exonucleolytic activity, which provides a proofreading-ability. Phi29 also has a strong strand displacement activity (Blanco et al., 1989 ) that allows for the complementary strand to be displaced during replication, consistently creating a new template for the amplification. The most widely used kit for RCA (Illustra TempliPhi, GE Healthcare Life Sciences) utilizes exonuclease-resistant random hexamers, however a recent study reported that the amplification of HPV DNA using TempliPhi could be improved by addition of nucleotides, since they were quickly depleted during the amplification process (Rector et al., 2004b) .
The use of random hexamers offers the possibility to amplify circular templates without any prior knowledge of the sequence, which has been advantageous in the discovery of new virus types. Consequently, this increases the risk of background amplification of other confounders present in the same sample, such as human genomic DNA. By designing degenerated HPV-specific primers using alignments for genital HPV types, we were able to increase the effectiveness of the RCA and the enrichment of HPV relative to human genomic DNA, as compared to using random hexamers. The RCA product was successfully sequenced without the need for cloning even when amplifying small amount of HPV-plasmid. We found this technique to be suitable for amplification of HPV DNA extracted from clinical FTA cards, providing sufficient template for subsequent Sanger sequencing to generate whole HPV genome sequences.
Results

Rolling circle amplification of HPV DNA
HPV-plasmids were used to evaluate the amplification efficiency of the RCA, and in order to mimic clinical samples, 10 ng of human gDNA was added to the HPV-plasmid. Gel electrophoresis of digested HPV-RCA products showed the presence of a fragment of the size expected for the entire HPV35-genome including the plasmid vector. RCA products were obtained for a range of starting amounts (Fig. 1A ) and verified to be HPV35 using RT-PCR (data not shown). Detectable levels of HPV DNA were obtained after 4 h of incubation; however levels increased considerably after 18 h. Two negative controls were also incubated for either 4 or 18 h and verified using RT-PCR (data not shown). Negative control 1, containing only background gDNA, produced a smear that was enhanced after 18 h of incubation due to lack of competition against HPV DNA for the primers used in RCA (Fig. 1A) . In negative control 2, no amplification product was seen after RCA (Fig. 1A) . The HPV-RCA was able to amplify a series of HPV types (HPV16, -18, -54, -56), representing different HPV groups (Fig. 1B) . These HPV-RCA products were sequenced using Protocol A and analyzed using BLAST. In each case the expected HPV sequence was detected (data not shown).
To evaluate the specificity of the HPV-RCA, as compared to random hexamer-RCA, we studied serial 10-fold dilutions of HPV35-plasmid in a background of 10 ng of high-molecular weight human gDNA. Product were digested and the number of HPV and human gDNA copies determined by RT-PCR (Gustavsson et al., 2009a) . Average enrichment by the HPV-RCA was 4.9 Â 10 5 -fold as compared to a 3.2 Â 10 4 -fold enrichment for hexamer-RCA. This represented a 15.2 times higher enrichment when using HPV-RCA ( Fig. 2A) . The enrichment of HPV DNA relative to human gDNA was on average 1.5 Â 10 5 -fold for HPV-RCA as compared to a 2.4 Â 10 3 -fold when using hexamer-RCA (Fig. 2B) .
Evaluation of mixed infection
To study RCA in samples containing multiple HPV types, plasmids containing HPV18 and HPV52 genomes were mixed in the ratios 1:1 (HPV18: HPV52), 4:1 (HPV18: HPV52) and 4:1 (linearized HPV18: circular HPV52). Pooled samples were used in the HPV-RCA, RE digested and the HPV copy numbers estimated by RT-PCR. Samples with a 1:1 ratio prior to RCA (Table 2: samples 1-3) showed a shift in ratio to 0.3:0.7, reflecting a preferential amplification of HPV52, although both HPV types were detectable. Samples with a ratio of 4:1 between HPV18 and HPV52 prior to RCA showed a ratio of 0.6:0.4, due to preferential amplification of HPV52, although the amount of HPV18 was still slightly higher than HPV52 (Table 2 ; samples 4-6). In the final series, a ratio of 4:1 between HPV18 and HPV52 prior to RCA was also used but the HPV18-plasmid was linearized by RE digest prior to mixing with HPV52. The amount of HPV18 after HPV-RCA was considerably reduced with HPV52 dominating ( 498%) ( Table 2 ; samples 7-9). Fig. 1 . RCA of HPV-plasmids using HPV-specific primers. (A) Concentrations of HPV35-plasmid ranging from 100 ng to 12.5 ng were used as template for RCA. Negative control 1 (Neg 1) contained 10 ng of gDNA and no HPV35 DNA, whereas negative control 2 (Neg 2) contained no DNA at all. Amplification was performed at 30 1C for either 4 or 18 h. (B) The degenerated HPV-specific primers were tested on HPV-plasmids from different species groups using 3 ng as template for RCA, and amplified for 18 h. L, 1 kb DNA ladder. 
HPV-genomic sequencing
The sequencing protocol was developed using 10-fold dilutions of HPV35-plasmid and included sequencing with two reverse and two forward primers. For each sample, four independent sequencing reactions were performed and average read length was calculated. RCA products from samples with high HPV copy numbers could be sequenced directly by diluting the product 60 times (Protocol A) (Table 3 ; samples 1 and 2). As input HPV copy numbers decreased below 10 5 copies the read length was shortened. Since the product obtained from RCA is concatemeric, high-molecular weight, linear, dsDNA, we hypothesized that this complex structure impeded the annealing of sequencing primers. By using RE digested RCA samples we were able to obtain high quality sequences using Protocol B from as little as 14,000 copies (0.2 pg) of HPV35-plasmid. When even lower copy numbers were used poor sequence results were obtained (Table 3 , sample 6).
HPV35-genome diversity
The optimized HPV-RCA protocol was evaluated using four clinical samples known to be infected solely with HPV35. Samples varied in copy numbers (10 4 -10 6 ), and hence were treated with either Protocol A or B prior to sequencing. To ensure that the HPV-RCA method did not introduce artefact substitutions, two independent HPV-RCAs were performed from the same DNA sample for individuals 1 (GenBank accession No. JX129485), 2 (GenBank accession No. JX129486) and 3 (GenBank accession No. JX129487) and each used to determine the full HPV-genome. Plus and minus strands were sequenced separately for the two independent RCAsamples and identical HPV sequences were obtained (Fig. 3 ). For individual 3 we also sequenced the full genome from the same RCA using either the plus or minus strand (3.1R and 3.1F) to confirm that Sanger sequencing did not introduce any sequence artefacts (Fig. 3) ; identical HPV sequences were obtained (Fig. 3 ).
Sample 4 (GenBank accession No. JX129488) was only sequenced for the minus strand. We found that all the samples differed from the HPV35 reference by nucleotide substitutions, deletions or large insertions. We detected a previously characterized insertion of 16 bp in the long control region (LCR) in two of the samples ( Fig. 3 ; individuals 1 and 2). Consistent with previous studies which reported that this insertion is less common in African populations, we did not detect this in individual 4 (Calleja-Macias et al., 2004 . A large deletion of 74 bp located in the LCR was also found in individual 1. The HPV35 sequence from individual 4, of South African origin, differs considerably from that of the three Swedish women, consistent with previous studies of some regions of HPV35 that have shown variation between populations (Calleja-Macias et al., 2004 . We found a total of 19 nucleotide substitutions which resulted in amino acid changes and these affected all of the coding regions except E7 (Fig. 3) .
Discussion
We have shown that the use of degenerated HPV-specific primers enhances the efficiency of the RCA up to 15.2 times as compared to random hexamers. Enrichment of the HPV-genome relative to human gDNA was also drastically enhanced. The HPV-RCA system successfully amplified HPV types from different species groups, supporting the utility of this system for a range of HPV types.
In order to evaluate the amplification efficiency of samples infected with multiple HPV types we studied synthetic mixtures of HPV-plasmids. The RCA successfully amplified both HPV types in a mixture, although with a slight preference for HPV52. In clinical samples with multiple infections, the ratio of HPV types may vary extensively, and our results indicate that for very skewed ratios, the lower frequency HPV type may be lost in the HPV-RCA. However, if typing information is available, one strategy to remove the effect of a type present at a high frequency is to linearize this Fig. 3 . Genome sequence diversity of HPV35. Four clinical samples were amplified using HPV-RCA and their genome sequenced. Samples 1-3 were collected in Sweden and sample 4 was collected in South Africa. For samples 1 and 2, two independent HPV-RCA reactions were performed for each sample and either sequenced using forward (F) or reverse (R) primers. For sample 3, two RCAs were also performed; one was sequenced by the reverse primers (3 R) and the other using either reverse (3.1R) or forward (3.1F) primers. Nucleotide substitutions are shown by the base affected, deletions by a hyphen and insertions by a white square for individuals lacking these insertions. Amino acid exchanges (AA) relative to the reference are indicated above each nucleotide substitution. genome prior to RCA, using a HPV type-specific RE. We showed this strategy to be quite efficient by linearizing HPV18 prior to RCA, resulting in a large excess of HPV52 as compared to o2% of HPV18. This strategy depends on the presence of a RE site that is unique for the major type.
Two protocols for sequencing of the RCA products were developed. High-copy number samples were simply diluted after RCA, whereas low-copy number samples were RE digested and cleaned before sequencing. As low as 14,000 copies of HPV-plasmid was successfully sequenced using Protocol B. Even lower copy numbers (1200) were possible to sequence, but with reduced quality and read length. Clinical samples were also amplified by HPV-RCA, generating high-quality genome sequences, and demonstrated the use of the FTA cards for large-scale studies. Comparison of the full genome sequence from independent HPV-RCA reactions generated from the same DNA sample, shows that the method is robust and does not introduce false substitutions. Comparison of clinical samples infected by HPV35 revealed a number of polymorphic sites, several of which have not previously been described and resulting in substitutions that alter the amino acid sequence. Furthermore, a previously characterized insertion of 16 bp in the LCR was found in two samples. In summary, the HPV-RCA results in an effective amplification of the full HPV-genome, with sufficient quantity and quality for full genome sequencing, even for clinical samples with low levels of oncogenic forms of HPV. Thus, this method is suitable for large-scale full-genome sequencing of oncogenic forms of HPV in clinical samples.
Materials and methods
HPV DNA samples
Plasmids containing the HPV16, À 18, À35, À52, À54, and À56 genomes were used for optimization of the RCA (Moberg et al., 2003) . Patient samples (n¼ 4), previously identified as solely positive for HPV35 were studied (Gustavsson et al., 2009a) . Three samples were from women attending gynecological screening in Uppsala, Sweden. This screening system is based on sample collection using a cytobrush and applied to a filter paper matrix, the indicating FTA elute micro card (WB 120411, GE Healthcare, United Kingdom) (Gustavsson et al., 2009b) . The fourth sample was from a black South African woman collected using a Digene cervical sampler (Mbulawa et al., 2010) .
Multiply-primed RCA
Alignments of genital HPV-genomes were generated from a HPV-sequence database (http://hpv-web.lanl.gov/, version 1997) and degenerated amplification primers were designed to cover well-conserved regions. Primers were protected by a thiophosphate modification between the last two nucleotides at the 3 0 end which increases their stability during RCA. The RCA (termed HPV-RCA) contained a premix of 23 HPV-specific primers (Table 1) at a final concentration of 0.4 mM each, 1X phi29 DNA polymerase buffer, 10 ng of human gDNA and dH 2 O in a final volume of 10 ml. When amplifying patient samples the same reaction mix was used except that no human gDNA was added to the premix and the final volume was adjusted with water.
Subsequently, 2 ml of DNA (plasmid or patient sample) was added to the premix, at varying concentrations ranging between 10 2 -10 9 HPV copies. Two negative controls were used by adding 2 ml dH 2 O as template, with one of the controls containing 10 ng of human gDNA (Negative 1) and the other containing no human gDNA (Negative 2). The DNA mixture including the HPV-specific primers, was denatured at 95 1C for 3 min and then cooled to 4 1C Primer name Table 2 RCA of synthetic HPV-plasmid mixtures. HPV18-and HPV52-plasmid were mixed in a ratio of 1:1 (samples 1-3), 4:1 (samples 4-6) or 4:1 using linearized HPV18 (samples 7-9). Plasmid mixtures were submitted to RCA using specific primers. before put on ice. The denatured sample was then added to 10 ml of the amplification solution which contained the 23 HPV-specific primers at a final concentration of 0.4 mM each, 1X phi29 DNA polymerase buffer, 2 ng/ml bovine serum albumin (BSA), 15 mM dNTPs, 2 U/ml of phi29 DNA polymerase (Thermo Scientific, Fermentas, Sweden) and dH 2 O. For samples with low-copy numbers collected from the FTA cards, the concentration of BSA was increased to 0.4 mg/ml. The sample was incubated at 30 1C for either 4 or 18 h, followed by inactivation of the enzyme at 65 1C for 10 min and then stored on ice. To evaluate the specific primers ability to reduce the background of human gDNA, an additional protocol (termed hexamer-RCA) was prepared by substituting the HPV-specific primers for 10 mM phosphorothioate modified random primers (hexamers) (Thermo Scientific, Custom Biopolymers, Germany); RCA was performed as described previously.
Restriction enzyme digestion of RCA product
The RCA product was digested with a restriction enzyme (RE) which cut the HPV-genome once. Ten ml of RCA product was added to 20 ml digestion mix containing 0.7 U/ml RE, 1x RE buffer and dH 2 O and incubated at 37 1C for 16 h, with a further 2 ml RE added after 2 h. Two ml of the digested RCA product was analyzed by electrophoresis on a 0.8% agarose gel stained with SYBR s Safe.
Real-time PCR assay
Type identification and quantification of the HPV copy number was performed using a real-time PCR assay (RT-PCR) (Gustavsson et al., 2009a) . This assay detects 12 high-risk HPV types and quantifies a human single copy gene, hydroxymethylbilane synthase. For each reaction, 3 ml of diluted RE sample was used and the quantification was performed as previously described (Gustavsson et al., 2009a) . To calculate the fold enrichment of HPV, the number of copies obtained after RCA was divided by the number of copies used as templates in the RCA. To determine the relative enrichment of HPV compared to human gDNA, the fold enrichment of HPV was divided by the fold enrichment of human gDNA.
Sequencing of RCA product
Two different protocols were used for the sequencing of RCA products. Protocol A was used for samples with greater than 10 6 copies prior to amplification, and was based on a 60-fold dilution of the RCA product and subsequent direct sequencing. Protocol B was used for samples with less than 10 6 copies prior to RCA. Each RCA product to be sequenced was RE digested and purified using 1 U Shrimp Alkaline Phosphatase and 10 U Exonuclease I (Thermo Scientific, Fermentas, Sweden) per 5 ml template. Incubation was at 37 1C for 15 min, followed by inactivation at 85 1C for 15 min. Sequencing was performed with BigDye s Terminator v3.1 chemistry (AB Applied Biosystems), using 3 ml DNA and 1.6 pmol of HPV35-specific primers (designed with Primer3 software, http:// flypush.imgen.bcm.tmc.edu/primer/). The sample was further purified by ethanol precipitation and analyzed on the ABI3730XL DNA Analyzer. Sequences were aligned against a reference HPV35 sequence (accession number: X74477) and quality of reads were obtained using the CodonCode software (version 3.7.1). The sequences described in this report were deposited in GenBank under the accession number JX129485, JX129486, JX129487 and JX129488.
